Amarin\'s Vascepa cuts total cardiovascular events by 30 percent in REDUCEIT trial httpswww.firstwordpharma.comnode1630098tsid28®ionid6Â
Amarin's Vascepa cuts total cardiovascular events by 30 percent in REDUCE-IT trial https://www.firstwordpharma.com/node/1630098?tsid=28®ion_id=6 …
More From BioPortfolio on "Amarin's Vascepa cuts total cardiovascular events by 30 percent in REDUCE-IT trial https://www.firstwordpharma.com/node/1630098?tsid=28®ion_id=6 …"